Biological and clinical evaluation of Lanreotide (BIM 23014), a somatostatin analogue, in the treatment of advanced breast cancer - A pilot study by the I.T.M.O. Group

Angelo Di Leo, Leonardo Ferrari, Emilio Bajetta, Cesare Bartoli, Giovanni Vicario, Daniele Moglia, Rosalba Miceli, Marina Callegari, Aldo Bono

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Biological data support the development of clinical trials designed to evaluate the activity of somatostatin (SMS) analogues in advanced breast cancer (ABC). Although previous clinical trials have failed to show antitumor activity, various factors may have biased their results. In an attempt to improve our understanding of the role of SMS analogues in ABC, 10 patients with favourable prognostic factors and who had not been heavily pretreated for advanced disease were treated with lanreotide 30 mg i.m. fortnightly (depot formulation). Blood samples were periodically taken to evaluate the effect of the drug on growth hormone (GH) and insulin-like growth factor 1 (IGF-1) and to determine drug serum levels. Although the drug was well tolerated, no clinical activity was observed. Serum GH and IGF-1 levels were not properly suppressed over time and drug serum concentrations fluctuated widely. In conclusion, SMS analogues cannot be recommended even as palliative treatment of ABC. Further studies should be undertaken to investigate the effect of higher drug doses, given subcutaneously or by means of continuous infusion, in suppressing GH and IGF-1 serum levels.

Original languageEnglish
Pages (from-to)237-244
Number of pages8
JournalBreast Cancer Research and Treatment
Volume34
Issue number3
DOIs
Publication statusPublished - Jun 1995

Fingerprint

Somatostatin
Breast Neoplasms
Somatomedins
Growth Hormone
Pharmaceutical Preparations
Serum
Clinical Trials
Therapeutics
Palliative Care
lanreotide

Keywords

  • advanced breast cancer
  • somatostatin analogues

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Biological and clinical evaluation of Lanreotide (BIM 23014), a somatostatin analogue, in the treatment of advanced breast cancer - A pilot study by the I.T.M.O. Group. / Di Leo, Angelo; Ferrari, Leonardo; Bajetta, Emilio; Bartoli, Cesare; Vicario, Giovanni; Moglia, Daniele; Miceli, Rosalba; Callegari, Marina; Bono, Aldo.

In: Breast Cancer Research and Treatment, Vol. 34, No. 3, 06.1995, p. 237-244.

Research output: Contribution to journalArticle

Di Leo, Angelo ; Ferrari, Leonardo ; Bajetta, Emilio ; Bartoli, Cesare ; Vicario, Giovanni ; Moglia, Daniele ; Miceli, Rosalba ; Callegari, Marina ; Bono, Aldo. / Biological and clinical evaluation of Lanreotide (BIM 23014), a somatostatin analogue, in the treatment of advanced breast cancer - A pilot study by the I.T.M.O. Group. In: Breast Cancer Research and Treatment. 1995 ; Vol. 34, No. 3. pp. 237-244.
@article{156e52e1b74d45df94975193c66e5cd7,
title = "Biological and clinical evaluation of Lanreotide (BIM 23014), a somatostatin analogue, in the treatment of advanced breast cancer - A pilot study by the I.T.M.O. Group",
abstract = "Biological data support the development of clinical trials designed to evaluate the activity of somatostatin (SMS) analogues in advanced breast cancer (ABC). Although previous clinical trials have failed to show antitumor activity, various factors may have biased their results. In an attempt to improve our understanding of the role of SMS analogues in ABC, 10 patients with favourable prognostic factors and who had not been heavily pretreated for advanced disease were treated with lanreotide 30 mg i.m. fortnightly (depot formulation). Blood samples were periodically taken to evaluate the effect of the drug on growth hormone (GH) and insulin-like growth factor 1 (IGF-1) and to determine drug serum levels. Although the drug was well tolerated, no clinical activity was observed. Serum GH and IGF-1 levels were not properly suppressed over time and drug serum concentrations fluctuated widely. In conclusion, SMS analogues cannot be recommended even as palliative treatment of ABC. Further studies should be undertaken to investigate the effect of higher drug doses, given subcutaneously or by means of continuous infusion, in suppressing GH and IGF-1 serum levels.",
keywords = "advanced breast cancer, somatostatin analogues",
author = "{Di Leo}, Angelo and Leonardo Ferrari and Emilio Bajetta and Cesare Bartoli and Giovanni Vicario and Daniele Moglia and Rosalba Miceli and Marina Callegari and Aldo Bono",
year = "1995",
month = "6",
doi = "10.1007/BF00689715",
language = "English",
volume = "34",
pages = "237--244",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York LLC",
number = "3",

}

TY - JOUR

T1 - Biological and clinical evaluation of Lanreotide (BIM 23014), a somatostatin analogue, in the treatment of advanced breast cancer - A pilot study by the I.T.M.O. Group

AU - Di Leo, Angelo

AU - Ferrari, Leonardo

AU - Bajetta, Emilio

AU - Bartoli, Cesare

AU - Vicario, Giovanni

AU - Moglia, Daniele

AU - Miceli, Rosalba

AU - Callegari, Marina

AU - Bono, Aldo

PY - 1995/6

Y1 - 1995/6

N2 - Biological data support the development of clinical trials designed to evaluate the activity of somatostatin (SMS) analogues in advanced breast cancer (ABC). Although previous clinical trials have failed to show antitumor activity, various factors may have biased their results. In an attempt to improve our understanding of the role of SMS analogues in ABC, 10 patients with favourable prognostic factors and who had not been heavily pretreated for advanced disease were treated with lanreotide 30 mg i.m. fortnightly (depot formulation). Blood samples were periodically taken to evaluate the effect of the drug on growth hormone (GH) and insulin-like growth factor 1 (IGF-1) and to determine drug serum levels. Although the drug was well tolerated, no clinical activity was observed. Serum GH and IGF-1 levels were not properly suppressed over time and drug serum concentrations fluctuated widely. In conclusion, SMS analogues cannot be recommended even as palliative treatment of ABC. Further studies should be undertaken to investigate the effect of higher drug doses, given subcutaneously or by means of continuous infusion, in suppressing GH and IGF-1 serum levels.

AB - Biological data support the development of clinical trials designed to evaluate the activity of somatostatin (SMS) analogues in advanced breast cancer (ABC). Although previous clinical trials have failed to show antitumor activity, various factors may have biased their results. In an attempt to improve our understanding of the role of SMS analogues in ABC, 10 patients with favourable prognostic factors and who had not been heavily pretreated for advanced disease were treated with lanreotide 30 mg i.m. fortnightly (depot formulation). Blood samples were periodically taken to evaluate the effect of the drug on growth hormone (GH) and insulin-like growth factor 1 (IGF-1) and to determine drug serum levels. Although the drug was well tolerated, no clinical activity was observed. Serum GH and IGF-1 levels were not properly suppressed over time and drug serum concentrations fluctuated widely. In conclusion, SMS analogues cannot be recommended even as palliative treatment of ABC. Further studies should be undertaken to investigate the effect of higher drug doses, given subcutaneously or by means of continuous infusion, in suppressing GH and IGF-1 serum levels.

KW - advanced breast cancer

KW - somatostatin analogues

UR - http://www.scopus.com/inward/record.url?scp=0028970079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028970079&partnerID=8YFLogxK

U2 - 10.1007/BF00689715

DO - 10.1007/BF00689715

M3 - Article

VL - 34

SP - 237

EP - 244

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -